LivaNova PLC (LIVN) Receives $80.17 Consensus PT from Brokerages
LivaNova PLC (NASDAQ:LIVN) has earned an average rating of “Hold” from the ten brokerages that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $80.17.
A number of research analysts recently issued reports on the stock. BidaskClub cut shares of LivaNova from a “buy” rating to a “hold” rating in a report on Saturday. Canaccord Genuity boosted their price objective on shares of LivaNova from $76.00 to $81.00 and gave the company a “hold” rating in a report on Tuesday, February 27th. ValuEngine cut shares of LivaNova from a “buy” rating to a “hold” rating in a report on Wednesday, December 20th. Needham & Company LLC restated a “buy” rating and set a $104.00 price objective (up previously from $97.00) on shares of LivaNova in a report on Wednesday, February 28th. Finally, Zacks Investment Research cut shares of LivaNova from a “hold” rating to a “strong sell” rating in a report on Thursday, January 25th.
Shares of LivaNova (LIVN) traded up $1.10 during midday trading on Friday, reaching $88.54. 191,610 shares of the company were exchanged, compared to its average volume of 399,556. The firm has a market capitalization of $4,286.29, a PE ratio of 25.14, a P/E/G ratio of 2.77 and a beta of 0.75. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.79 and a current ratio of 2.14. LivaNova has a 52-week low of $48.16 and a 52-week high of $92.31.
In other news, Director Daniel Jeffrey Moore sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $83.32, for a total value of $83,320.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 3,000 shares of company stock valued at $246,270 in the last quarter. Corporate insiders own 0.28% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. Rehmann Capital Advisory Group acquired a new position in shares of LivaNova in the fourth quarter valued at approximately $216,000. Segall Bryant & Hamill LLC acquired a new position in shares of LivaNova in the fourth quarter valued at approximately $291,000. Castleark Management LLC bought a new stake in shares of LivaNova in the fourth quarter worth $8,304,000. Macquarie Group Ltd. lifted its position in shares of LivaNova by 100.0% in the fourth quarter. Macquarie Group Ltd. now owns 2,800 shares of the company’s stock worth $224,000 after purchasing an additional 1,400 shares in the last quarter. Finally, Zeke Capital Advisors LLC bought a new stake in shares of LivaNova in the fourth quarter worth $241,000. Institutional investors own 85.52% of the company’s stock.
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.